Document is current
Any future updates will be listed below
-
Authors
Adjei, Jonathan Kofi
Aniagyei, Wilfred
Adankwah, Ernest
Seyfarth, Julia
Mayatepek, Ertan
Berko, Daniel Antwi
Ackam, Nancy
Annani-Akollor, Max Efui
Sakyi, Samuel Asamoah
Amoako, Yaw Ampem
Owusu, Dorcas
Jacobsen, Marc
Phillips, Richard Odame
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (JA 1479/5-1, JA 1479/5-1)
European and Developing Countries Clinical Trials Partnership (101897 BuruliNox 7, 101897 BuruliNox 7, 101897 BuruliNox 7)
- License Information
-
More Information
Article History
Received: 4 February 2023
Accepted: 3 June 2023
First Online: 12 June 2023
Declarations
:
: Ethical approval for the study was obtained from the Committee on Human Research, Publication and Ethics (CHRPE) at the School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana (Approval number: CHRPE/AP/275/14 and CHRPE/AP/301/15). In addition, ethical approval was granted by the Ethical committee of the medical faculty of the Heinrich-Heine-University Dusseldorf (Approval number: 3903). The aims and procedures were explained to participants and/or their parents/guardians prior recruitment into the study. Only compliant patients were recruited and they were free to withdraw at any point during the study. Written informed consent was obtained from the parents or guardians of all minor participants. In some cases (illiterate guardians/parents) consent was confirmed by thumbprint, a procedure approved by the Committee on Human Research, Publication and Ethics (CHRPE) at the School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. All methods and study procedures were carried out in accordance with relevant guidelines and regulations as enshrined in the Declaration of Helsinki [].
: Not applicable.
: The authors declare no competing interests.
